News
HRTX
3.440
+1.18%
0.040
Weekly Report: what happened at HRTX last week (0513-0517)?
Weekly Report · 1d ago
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
NASDAQ · 4d ago
Heron Therapeutics Price Target Maintained With a $5.00/Share by Needham
Dow Jones · 5d ago
Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Benzinga · 5d ago
Analysts Are Bullish on These Healthcare Stocks: AN2 Therapeutics, Inc. (ANTX), Heron Therapeutics (HRTX)
TipRanks · 6d ago
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
NASDAQ · 6d ago
Weekly Report: what happened at HRTX last week (0506-0510)?
Weekly Report · 05/13 11:08
Heron Therapeutics Price Target Maintained With a $5.00/Share by Needham
Dow Jones · 05/08 09:46
Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Benzinga · 05/08 09:35
Heron Therapeutics: A Strong Buy on Surging Sales and Strategic Partnerships
TipRanks · 05/07 18:56
HRTX Stock Earnings: Heron Therapeutics Beats EPS, Beats Revenue for Q1 2024
Heron Therapeutics reported earnings per share of -2 cents for the first quarter of 2024. The company reported revenue of $34.67 million. This was 5.70% better than the analyst estimate of $32.80 million. Heron Therapedutics reported results for first quarter 2024.
Investorplace · 05/07 16:54
Heron Therapeutics, Inc. Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 05/07 13:25
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 05/07 13:05
Heron Therapeutics Inc: Current report
Press release · 05/07 12:29
HERON THERAPEUTICS SHARES UP 5% PREMARKET AFTER Q1 RESULTS
Reuters · 05/07 12:08
*Heron Therapeutics Still Sees 2024 Net Product Revenue $138M-$158M >HRTX
Dow Jones · 05/07 12:06
*Heron Therapeutics 1Q Loss $3.16M >HRTX
Dow Jones · 05/07 12:05
*Heron Therapeutics 1Q Sales $34.7M >HRTX
Dow Jones · 05/07 12:05
Press Release: Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates. Heron to host its first ever Investor Day event on Wednesday, May 15, 2024 in New York, New York. The company announced net product sales of $34.7 million for the three months ended March 31, 2024. FDA approval of expanded indication for ZYNRELEF received on January 23, 2024 and expected to be approved in late 2024.
Dow Jones · 05/07 12:01
Press Release: Heron Therapeutics Announces First -3-
There are more than 220,000,000 dollars in assets and liabilities. The total number of assets is more than 200,000. The number of liabilities is over 100,000 and the total liabilities are over 50,000 The total value of the company's assets is over $200 million. The company has a total of $1.2 billion in cash and investments.
Dow Jones · 05/07 12:01
More
Webull provides a variety of real-time HRTX stock news. You can receive the latest news about Heron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.